Keytruda killer Ivonescimab valued at $17B pre-approval.
Yet PD-1/VEGF bispecifics do not activate T cells or make cold tumors hot.When PD-1/VEGF hit wall, dendritic cells prime & heat the tumor activating T cells enabling bispecifics to work.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $365.0M | |||
| Open | High | Low | Value | Volume |
| 24.5¢ | 25.0¢ | 24.0¢ | $85.77K | 350.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 44640 | 24.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 25.0¢ | 216415 | 15 |
View Market Depth
| Last trade - 12.52pm 18/06/2025 (20 minute delay) ? |
| IMM (ASX) Chart |